• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Invacare Corporation

    6/6/23 4:48:43 PM ET
    $IVC
    Industrial Specialties
    Health Care
    Get the next $IVC alert in real time by email
    S-8 1 june2023s8.htm S-8 Document

    As filed with the Securities and Exchange Commission on June 6, 2023
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM S-8

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    INVACARE HOLDINGS CORPORATION
    (Exact name of Registrant as specified in its charter)
    Delaware38-4264819
    (State or other Jurisdiction of
    Incorporation or Organization)
    (I.R.S. Employer
    Identification Number)
    One Invacare Way Elyria, Ohio 44035
    (Address of Principal Executive Offices) (Zip Code)
    INVACARE HOLDINGS CORPORATION 2023 MANAGEMENT INCENTIVE PLAN
    (Full Title of the Plan)
    Anthony C. LaPlaca
    Senior Vice President, General Counsel,
    Chief Administrative Officer and Secretary
    One Invacare Way
    Elyria, Ohio 44035 (440) 329-6000

    (Name, address,and telephone number, including area code,
    of agent for service)
    Copy to:
    Catherine Gardner, Esq.
    Brown Rudnick LLP
    7 Times Square
    New York, NY 10036
    (212) 209-4800
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “small reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.    
    Large accelerated filer
    o
    Accelerated filer
    o
    Non-accelerated filerþSmaller reporting companyþ
    Emerging growth company
    o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
    Securities Act.o






    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The documents containing the information specified in Part I will be sent or given to participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. In accordance with the Note under Part I of Form S-8, such documents will not be filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute the prospectus required by Section 10(a) of the Securities Act.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

        The following documents filed with the SEC by the Registrant pursuant to the Securities Act and Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:

    a.The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on April 14, 2023 (the “Form 10-K”);

    b.The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on May 15, 2023;

    c.the current Reports on Form 8-K and Form 8-K12G3 filed with the SEC, respectively, by the Registrant's predecessor on May 2, 2023 (excluding any information furnished therein) and by the Registrant on May 8, 2023; and

    d.the description of the Registrant's Common Stock set forth in Item 5.03 of the aforementioned Form 8-K12G3 filed with the SEC on May 8, 2023.

        All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports on Form 8-K, or portions thereof, that are deemed to be furnished and not files), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

        Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    ITEM 4. DESCRIPTION OF SECURITIES

    Not applicable.

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

    Not applicable.

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

    Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”) allows a corporation to eliminate the personal liability of a director or officer of a corporation to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director or officer breached his or her duty of loyalty to the corporation or its
    1


    stockholders, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, obtained an improper personal benefit, or (in the case of a director) authorized the payment of a dividend or approved a stock purchase or redemption in violation of Delaware corporate law.

    Section 145 of the DGCL provides, among other things, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the corporation’s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action, suit or proceeding. The power to indemnify applies (i) if such person is successful on the merits or otherwise in defense of any action, suit or proceeding or (ii) if such person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. The power to indemnify applies to actions brought by or in the right of the corporation as well, but only to the extent of defense expenses (including attorneys’ fees, but excluding amounts paid in settlement) actually and reasonably incurred and not to any satisfaction of judgment or settlement of the claim itself, and with the further limitation that in such actions no indemnification shall be made in the event of any adjudication of negligence or misconduct in the performance of the person’s duties to the corporation, unless a court believes that in light of all the circumstances indemnification should apply.

    Section 174 of the DGCL provides, among other things, that a director who willfully and negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was absent when the unlawful actions were approved or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered on the books containing the minutes of the proceedings of the board of directors at the time the action occurred or immediately after the absent director receives notice of the unlawful acts.

    Article VIII of the Registrant’s Amended and Restated Certificate of Incorporation (the “COI”) provides that, to the fullest extent permitted by the DGCL as from time to time amended, a director or officer of the Registrant shall not be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director or officer.

    Article VII of the Registrant’s COI provides that the Registrant shall indemnify any person who is a party to, or is threatened to be made a party to, any threatened, pending, or completed action, suit or proceeding (a “Proceeding”), other than an action by or in the right of the Registrant, by reason of the fact that such person is or was a director or officer of the Registrant, or while a director or officer of the Registrant, is or was serving at the Registrant’s request as a director, officer, employee, fiduciary or agent of another corporation, partnership, joint venture, limited liability company, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amount paid in settlement actually and reasonably incurred by the person in connection with such Proceeding if the person acted in good faith and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the Registrant and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful; provided, however, that certain restrictions and conditions apply if indemnification is sought in connection with a Proceeding commenced by the person seeking such indemnification; and provided, further, that certain expenses shall, in specified circumstances, be indemnified to such persons in connection with actions or suits by or in the right of the Registrant. The indemnification provisions contained in the Registrant’s COI are not exclusive of any other rights to which a person may be entitled by law, agreement, vote of stockholders or disinterested directors or otherwise.

    The Registrant has also entered into indemnification agreements with each of its directors. These agreements are intended to provide the maximum protection permitted by Delaware law with respect to indemnification of directors. The Registrant may also enter into similar agreements with certain of its officers who are not also directors. The effect of these provisions is to permit indemnification by the Registrant for liabilities arising under the Securities Act. The Registrant also maintains directors’ and officers’ liability insurance.

    The foregoing summaries are necessarily subject to the complete text of the statute, the COI, and the agreements referred to above and are qualified in their entirety by reference thereto.

    ITEM 7.     EXEMPTION FROM REGISTRATION CLAIMED

    Not applicable.

    ITEM 8. EXHIBITS

    The information contained in the Exhibit Index immediately preceding the signatures at the end of this Registration
    2


    Statement is hereby incorporated by reference.

    ITEM 9. UNDERTAKINGS

    (a) The undersigned Registrant hereby undertakes:

    1.To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    i.To include any prospectus required by Section 10(a)(3) of the Securities Act;

    ii.To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

    iii.To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    Provided, however, that paragraphs (1)(i) and (1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    2.That, for the purpose of determining any liability under the Securities Act each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.












    3




    SIGNATURES

        Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Elyria, Ohio, on June 6, 2023.

      INVACARE HOLDINGS CORPORATION
    By:/s/ Kathleen P. Leneghan
       Kathleen P. Leneghan
       Senior Vice President and Chief Financial Officer
        

    POWER OF ATTORNEY AND SIGNATURES

    Each person whose signature appears below hereby severally constitutes and appoints Geoffrey P. Purtill, Kathleen P. Leneghan, and Anthony C. LaPlaca, and each of them singly, with the power to act without the other, as attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendment to this Registration Statement and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to said attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    4


    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.
    Signature  TitleDate
    /s/ Geoffrey P. Purtill  President and Chief Executive Officer and Director (Principal Executive Officer)June 6,2023
    Geoffrey P. Purtill
    /s/ Kathleen P. LeneghanSenior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)June 6,2023
    Kathleen P. Leneghan
    /s/ Steven H. Rosen  ChairmanJune 6,2023
    Steven H. Rosen
    /s/ Marec E. EdgarDirectorJune 6,2023
    Marec E. Edgar
    /s/ Abraham T. Han  DirectorJune 6,2023
    Abraham T. Han
    /s/ Peter J. KuipersDirectorJune 6,2023
    Peter J. Kuipers
    /s/ Kimberly S. Lody  DirectorJune 6,2023
    Kimberly S. Lody
    /s/ Randel G. Owen  DirectorJune 6,2023
    Randel G. Owen


    5


    INVACARE HOLDINGS CORPORATION
    EXHIBIT INDEX

    The following exhibits are filed as part of or incorporated by reference into this Registration Statement:

    Exhibit NumberExhibit
    Description
    4.1
    Amended and Restated Certificate of Incorporation of Invacare Holdings Corporation (incorporated by reference to Exhibit 3.1 filed by the Registrant with the Current Report on Form 8-K12G3 on May 8, 2023).
    4.2
    Amended and Restated Bylaws of Invacare Holdings Corporation (incorporated by reference to Exhibit 3.2 filed by the Registrant with the Current Report on Form 8-K12G3 on May 8, 2023).
    5.1
    Opinion of Brown Rudnick LLP, as to legality of the securities being registered (filed herewith).
    23.1
    Consent of Ernst & Young LLP, independent registered public accounting firm (filed herewith).
    23.2
    Consent of Brown Rudnick LLP (included in Exhibit 5.1 of this Registration Statement).
    24.1
    Power of attorney (included on the signature pages of this Registration Statement).
    107
    Filing Fee Table (filed herewith).


    E-1
    Get the next $IVC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVC

    DatePrice TargetRatingAnalyst
    10/29/2021$11.00 → $9.00Outperform
    Oppenheimer
    9/10/2021$17.00 → $8.00Buy
    Needham
    8/19/2021$11.00Outperform
    Oppenheimer
    More analyst ratings

    $IVC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Invacare Corporation Takes Action to Strengthen Its Financial Position and Drive Long-Term Growth Through Voluntary Prearranged Chapter 11 Cases That Do Not Include Its International Operations

      Refinancing action will reduce net debt by approximately 65% Global manufacturing and delivery of products to continue uninterrupted to meet robust customer demand Strong sequential improvement achieved in preliminary 4Q22 financial results Executed strategic actions accelerating a renewed focus on core businesses Invacare Corporation (NYSE:IVC) ("Invacare" or "the company"), a leading manufacturer and distributor of medical equipment used in non-acute care settings, today announced actions to strengthen the company and position it for long-term success. To facilitate its financial restructuring, the company has entered into a Restructuring Support Agreement (the "RSA" or "Agreement")

      2/1/23 8:33:00 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation Announces Additional Draw of Term Loans

      Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") announced the consummation of an additional draw of $5,500,000 of term loans under to its Credit Agreement with certain funds managed by Highbridge Capital Management LLC ("Highbridge"), as of December 23, 2022. Commenting on the financing, Geoff Purtill, president and chief executive officer stated, "As guided in the 3Q22 earnings release, Europe achieved sequential growth in revenues and profitability driven by improved supply chain circumstances giving us confidence that our transformation program is reaping benefits. Today's announcement provides us with greater flexibility as we execute against our stated strategy. We are p

      12/27/22 8:02:00 AM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Invacare Appoints Geoff Purtill President and Chief Executive Officer

      Invacare Corporation (NYSE:IVC) announced today that its Board of Directors has named Geoffrey P. Purtill as President and Chief Executive Officer, roles that he has served on an interim basis since August 28, 2022. Non-executive Chairman of the Board of Directors Michael J. Merriman, Jr, said, "On behalf of the Board, we are excited to elevate Geoff Purtill into the role of President and CEO. The Board determined that Geoff is the right steward of the company as it undergoes significant transformation and embarks on a new chapter. Geoff has proven adept at guiding our global businesses through change, both in his previous role overseeing the EMEA and APAC businesses, and now in his curren

      11/21/22 5:03:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation Announces Executive Leadership Changes

      Appoints Geoff Purtill as Interim Chief Executive Officer and Michael Merriman as Board Chairman Invacare Corporation (NYSE:IVC) today announced changes to its senior management team and Board of Directors to advance its previously announced business transformation initiatives, address supply chain challenges, and strengthen its financial performance. Geoffrey P. Purtill, who had been serving as the company's Senior Vice President and General Manager, EMEA and APAC, was named interim President and Chief Executive Officer, replacing Matthew E. Monaghan, who has left from his role as Chairman, President and Chief Executive Officer, effective August 28, 2022. The Board of Directors has comme

      8/29/22 7:35:00 AM ET
      $AM
      $IVC
      $NDSN
      $RGS
      Natural Gas Distribution
      Utilities
      Industrial Specialties
      Health Care

    $IVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

      SC 13D/A - INVACARE HOLDINGS Corp (0000742112) (Subject)

      2/15/24 9:03:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

      SC 13D/A - INVACARE HOLDINGS Corp (0000742112) (Subject)

      2/15/24 9:00:49 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Invacare Corporation (Amendment)

      SC 13D/A - INVACARE HOLDINGS Corp (0000742112) (Subject)

      2/15/24 9:00:18 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Davidson Kempner Capital Management Lp claimed ownership of 717,650 shares (SEC Form 3)

      3 - INVACARE HOLDINGS Corp (0000742112) (Issuer)

      2/12/24 4:15:59 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Ferreira Cintia was granted 84,000 shares (SEC Form 4)

      4 - INVACARE HOLDINGS Corp (0000742112) (Issuer)

      11/3/23 5:15:51 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Purtill Geoffrey was granted 1,204,000 shares (SEC Form 4)

      4 - INVACARE HOLDINGS Corp (0000742112) (Issuer)

      11/3/23 5:13:41 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Financials

    Live finance-specific insights

    See more
    • Invacare Reports Results for Third Quarter 2022

      Updates strategic priorities with the discontinuation of the production of respiratory products Anticipates sequential improvement in revenues and profitability in 4Q22 Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") today reported results for the quarter ended September 30, 2022. Executive Summary Reflecting on the quarter and the company's progress against its transformation program, Geoffrey Purtill, interim president and chief executive officer, said "We remain committed to taking necessary and decisive action to increase shareholder value. After carefully evaluating our strategic options, we have determined that the lifestyle and mobility & seating categories are core

      11/7/22 4:15:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results

      Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") announces that it will release its financial results for the third quarter ended September 30, 2022, after the market closes on Monday, November 7, 2022. The company will provide a live conference call and webcast to discuss these financial results on Tuesday, November 8, 2022, at 8:30 AM ET. Investors and other interested parties may access the webcast and conference call in the following ways: Those wishing to participate via webcast can register and access the event at https://events.q4inc.com/attendee/918973030 Those wishing to participate via telephone can dial 844-200-6205 (U.S. and Canada) or 929-526-1599 (internation

      10/20/22 8:00:00 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Reports Results for Second Quarter 2022

      Achieved sequential improvement in profitability and free cash flow Invacare Corporation (NYSE:IVC) ("Invacare" or the "company") today reported results for the quarter ended June 30, 2022. Executive Summary Reflecting on the quarter, Matt Monaghan, chairman, president, and chief executive officer, said "In 2Q22, we achieved sequential revenue growth of 4.7% in mobility & seating products driven by increased adoption of our compelling product portfolio. We continue to experience elevated backlog across all product categories and regions, and see strong demand in mobility & seating and lifestyle products. We are working diligently to increase output and convert order backlog into sales.

      8/8/22 4:20:00 PM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer reiterated coverage on Invacare with a new price target

      Oppenheimer reiterated coverage of Invacare with a rating of Outperform and set a new price target of $9.00 from $11.00 previously

      10/29/21 7:39:40 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Needham reiterated coverage on Invacare with a new price target

      Needham reiterated coverage of Invacare with a rating of Buy and set a new price target of $8.00 from $17.00 previously

      9/10/21 5:41:14 AM ET
      $IVC
      Industrial Specialties
      Health Care
    • Oppenheimer initiated coverage on Invacare with a new price target

      Oppenheimer initiated coverage of Invacare with a rating of Outperform and set a new price target of $11.00

      8/19/21 7:41:53 AM ET
      $IVC
      Industrial Specialties
      Health Care

    $IVC
    SEC Filings

    See more
    • Invacare Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - INVACARE HOLDINGS Corp (0000742112) (Filer)

      2/16/24 5:16:23 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • SEC Form NT 10-Q filed by Invacare Corporation

      NT 10-Q - INVACARE HOLDINGS Corp (0000742112) (Filer)

      11/15/23 4:06:00 PM ET
      $IVC
      Industrial Specialties
      Health Care
    • Invacare Corporation filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits

      8-K - INVACARE HOLDINGS Corp (0000742112) (Filer)

      9/13/23 4:31:43 PM ET
      $IVC
      Industrial Specialties
      Health Care